Want to join the conversation?
Drugmaker $VRTX reported a narrower 2Q16 loss driven by product revenue from cystic fibrosis treating drugs Orkambi and Kalydeco. Net loss narrowed to $64.53MM or $0.26 per share from $188.85MM or $0.78 per share last year. Revenue grew to $431.61MM from $166.08MM. Non-GAAP EPS was $0.24 compared to loss of $0.54 per share a year ago.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.
$RAI has received a $47 billion take over offer from British tobacco giant British American Tobacco! This is huge!